PMID: 9184704Jun 1, 1997Paper

Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control

The Annals of Pharmacotherapy
S F GardnerV A Fonseca

Abstract

To determine the efficacy and tolerability of the addition of low-dose niacin (1.5 g/d) in a diabetic hypercholesterolemic population who were unable to attain desired lipid control with low-dose (20 mg) pravastatin monotherapy. This was a prospective, open-label study conducted over a 14-week period. Twenty-three diabetic patients with low-density lipoprotein (LDL) cholesterol concentrations of at least 150 mg/dL after dietary therapy were recruited from the outpatient diabetes clinic of a university teaching hospital. After 4 weeks of dietary stabilization and baseline determination of the lipid profile and glycemic control, patients received pravastatin 20 mg once daily for 4 weeks. Laboratory parameters were reassessed and niacin was added to the regimen in qualifying patients. Over 2 weeks, patients' regimens were titrated to a maximal dosage of 500 mg tid. Patients continued to receive the combination regimen for 4 weeks and were reassessed. Sixteen patients (14 non-insulin-dependent diabetes mellitus, 2 insulin-dependent diabetes mellitus) completed the study. Mean fasting blood sugar and fructosamine concentrations were unchanged throughout the study. Five patients required minor alterations (3 increased, 2 decreased) i...Continue Reading

References

Jan 1, 1992·The American Journal of Medicine·J I RaderJ N Hathcock
Sep 1, 1991·The American Journal of Medicine·Y HenkinJ P Segrest
Mar 1, 1967·The Journal of Clinical Endocrinology and Metabolism·E J Pinter, C J Pattee
Jul 1, 1996·Diabetes·R W Stout
Jan 1, 1959·The American Journal of the Medical Sciences·H GURIAN, D ADLERSBERG
Feb 1, 1964·Metabolism: Clinical and Experimental·G D MOLNARR W ACHOR
Feb 1, 1955·Archives of Biochemistry and Biophysics·R ALTSCHULJ D STEPHEN

❮ Previous
Next ❯

Citations

Aug 10, 2000·Drugs·P H Chong, B S Bachenheimer
Jun 30, 2006·International Journal of Clinical Practice·H Oberwittler, M Baccara-Dinet
Dec 21, 2000·Current Atherosclerosis Reports·D M CapuzziC M Intenzo
Oct 9, 2002·Current Medical Research and Opinion·Jeannette M Goguen, Lawrence A Leiter
Dec 21, 2000·Current Atherosclerosis Reports·K AlaswadR M Moe
Aug 7, 2001·Current Atherosclerosis Reports·T A Jacobson
Dec 31, 2002·The Annals of Pharmacotherapy·Barbara T Yim, Pang H Chong
Jul 21, 2004·Endocrinology and Metabolism Clinics of North America·Gloria Lena Vega

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.